Suma Sri Chennnapragada

Hematology-Oncology fellow LSU Shreveport |Clinical research| Cancer awareness

[Suma Sri Chennnapragada @SChenspeaks]

Spent the weekend refreshing updates from # ASCO2025
It was wonderful to have the “Best of ASCO” meeting in Shreveport this year !
Thanks to the @binaytara @binayshah foundation for this event! Their work on cancer disparities is truly inspiring…

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[Suma Sri Chennnapragada @SChenspeaks]

Concerning trends of early onset colon cancer
Read our study here :

https://t.co/nPENEWT4GA

[Suma Sri Chennnapragada @SChenspeaks]

@MDHemeonc 👏 congratulations

[Suma Sri Chennnapragada @SChenspeaks]

Excited to share that I am board certified in Hematology now !!
I was doubtful if I could even give the boards this year with all the other responsibilities I had but some days you just have to trust yourself and your support system 😇
#hematologyboardcertified

[Nazli Dizman @NazliDizman]

🎉Immensely excited and proud to share with you our recent paper "Guide to Understanding and Supporting #InternationalMedicalGraduates in #Hematology #Oncology" with gratitude to my co-first author @ZiadBakouny, senior authors @DrChoueiri #DrAlfredLee, and other world-renowned co-authors, @IMG_Oncologists #IMGCoP @ASCO @JCOOP_ASCO #IMG

👉https://t.co/Tq0boQ3nAB

🙏🙏@TarekHaykal1 @IvyLorena_Md @ADesaiMD @AyeshaButtMD @arnabguonc @DanZhaoMD @eddy_saad @ReneeSaliby @OncBrothers @ArdeshirFatemeh @LeiDeng3 @luvpooh101 @KArnaoutakis @GIcancerDoc @RManochakian @AMarshallMD @FordePatrick @DrMMurphy @VivekSubbiah #DrChavezMacGregor @teekayowo @GlopesMd @CharuAggarwalMD @ASridharMD @DrKarineTawagi @KarunNeupaneMD @royaryam @drtulsijose @CharlesJiangMD @ASCOTECAG @FernandoDiazMD1 @KMittalmd @ziremozay @yekeduz_emre @Noha_Soror

[Suma Sri Chennnapragada @SChenspeaks]

Happy to share our latest publication!

We have tried to establish some crucial risk factors for the development of non-hodgkin lymphoma in patients with autoimmune diseases
@ShriyaGoyal5 @ShivaniMD @Saloni2509 @stpbystpgrowth @UpasanaAgrawal_

https://t.co/ooj9sFw2b6

[Suma Sri Chennnapragada @SChenspeaks]

@cardiologyFIT That’s awesome
Congratulations and good luck !

[Suma Sri Chennnapragada @SChenspeaks]

Another year
Another July 1st
Some added responsibilities…
Excited to step into my last year of training as a chief fellow !
#PGY6

[Suma Sri Chennnapragada @SChenspeaks]

@cardiologyFIT Thank you rahul ! Long time ! Hope you are doing good

[Suma Sri Chennnapragada @SChenspeaks]

My first textbook chapter published!
An important topic for all clinicians as these antibodies are becoming more And prevalent

https://t.co/ITmIXSDCMD

[Suma Sri Chennnapragada @SChenspeaks]

@Saloni2509 @ASCO @hemeoncfellow @arpita_pawa 👏👏

[Suma Sri Chennnapragada @SChenspeaks]

@stpbystpgrowth @AshwiniG2188 They sure do 😋

[Suma Sri Chennnapragada @SChenspeaks]

A trip to chicago is not complete without a stop at the good old Nando’s 😉

[Suma Sri Chennnapragada @SChenspeaks]

Day 2 at @ASCO 2024
Some exciting plenary sessions and catching up with friends from all over!
It’s great to see pathbreaking research in lung cancer which has always starved for new treatments!
@ShivaniMD @KalantriShreyas

[Suma Sri Chennnapragada @SChenspeaks]

Day 1 at @ASCO 2024!
Career sessions and lots of learning

[Suma Sri Chennnapragada @SChenspeaks]

@UGrewalMD @UIowaCancer Congratulations @UGrewalMD

[Shivani Sharma, MD, MPH @ShivaniMD]

Our work on the importance of comprehensive mutation testing in patients with Essential Thrombocythemia
@nitesh_gandhi25 @SChenspeaks

https://t.co/R7UpICxIHt

[Suma Sri Chennnapragada @SChenspeaks]

@ASH_hematology 2023 meeting was a great learning experience
With some amazing collaborative work I had a total of 5 posters this year
It was fun meeting up with friends and researchers from all over the world
@RoboDoctr @ShivaniMD @Saloni2509 @ShriyaGoyal5 @arcitahanjani

[NEJM @NEJM]

Late breaking at #ASH23:

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma. Full PERSEUS trial results: